RxDoctor Payments Data

Michael Adamo, DO

Internal Medicine · Ft Worth, TXNPI 1649281296

Payments from drug & device makers

$794in general payments, 2019–2025

Across 41 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$354
  • Novartis$95
  • Johnson & Johnson$68
  • Dexcom, Inc.$53
  • Lilly USA, LLC$40
  • Eisai Inc.$30
  • plus $154 from 8 others

What the payments were for

  • Food & beverage$794100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$794 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$210,869
Medicare patients
301
Services billed
2,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$62,165
JardianceEmpagliflozin69$46,618
OzempicSemaglutide28$32,981
XareltoRivaroxaban32$17,804
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$14,318
EntrestoSacubitril/Valsartan16$13,201
JanuviaSitagliptin Phosphate11$10,791
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$9,087
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$7,214
PremarinEstrogens, Conjugated13$5,045
LantusInsulin Glargine,hum.Rec.Anlog21$4,213
VascepaIcosapent Ethyl12$4,188
Humalog Kwikpen U-100Insulin Lispro11$3,385
Levemir FlexpenInsulin Detemir14$3,065
SymbicortBudesonide/Formoterol Fumarate13$2,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$25$67,210101 claims
Boehringer IngelheimJardiance$16$46,61869 claims
Novo NordiskOzempic$27$32,98128 claims
Johnson & JohnsonXarelto$68$17,80432 claims
NovartisEntresto$95$13,20116 claims
Sanofi-aventis U.S. LLCLantus$15$4,21321 claims
AstraZenecaSymbicort$13$2,96513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Ft Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →